TITLE

Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells

AUTHOR(S)
Bin Zhang; Ling Li; Yinwei Ho; Min Li; Marcucci, Guido; Wei Tong; Bhatia, Ravi; Zhang, Bin; Li, Ling; Ho, Yinwei; Li, Min; Tong, Wei
PUB. DATE
March 2016
SOURCE
Journal of Clinical Investigation;3/1/2016, Vol. 126 Issue 3, p975
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Chronic myelogenous leukemia (CML) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR-ABL fusion gene. However, BCR-ABL-expressing LTHSCs are heterogeneous in their capacity as leukemic stem cells (LSCs). Although discrepancies in proliferative, self-renewal, and differentiation properties of normal LTHSCs are being increasingly recognized, the mechanisms underlying heterogeneity of leukemic LTHSCs are poorly understood. Using a CML mouse model, we identified gene expression differences between leukemic and nonleukemic LTHSCs. Expression of the thrombopoietin (THPO) receptor MPL was elevated in leukemic LTHSC populations. Compared with LTHSCs with low MPL expression, LTHSCs with high MPL expression showed enhanced JAK/STAT signaling and proliferation in response to THPO in vitro and increased leukemogenic capacity in vivo. Although both G0 and S phase subpopulations were increased in LTHSCs with high MPL expression, LSC capacity was restricted to quiescent cells. Inhibition of MPL expression in CML LTHSCs reduced THPO-induced JAK/STAT signaling and leukemogenic potential. These same phenotypes were also present in LTHSCs from patients with CML, and patient LTHSCs with high MPL expression had reduced sensitivity to BCR-ABL tyrosine kinase inhibitor treatment but increased sensitivity to JAK inhibitors. Together, our studies identify MPL expression levels as a key determinant of heterogeneous leukemia-initiating capacity and drug sensitivity of CML LTHSCs and suggest that high MPL-expressing CML stem cells are potential targets for therapy.
ACCESSION #
113546799

 

Related Articles

  • Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation. Bedel, Aurélie; Pasquet, Jean- Max; Lippert, Éric; Taillepierre, Miguel; Lagarde, Valérie; Dabernat, Sandrine; Dubus, Pierre; Charaf, Lucie; Beliveau, François; de Verneuil, Hubert; Richard, Emmanuel; Mahon, François-Xavier; Moreau-Gaudry, François // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. However, the majority of patients achieving remission with TKI still have molecular evidences of disease persistence. Various...

  • MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. Nan Zhu; Mo Chen; Rowena Eng; DeJong, Joshua; Sinha, Amit U.; Rahnamay, Noushin F.; Koche, Richard; Al-Shahrour, Fatima; Minehart, Janna C.; Chun-Wei Chen; Deshpande, Aniruddha J.; Haiming Xu; Chu, S. Haihua; Ebert, Benjamin L.; Roeder, Robert G.; Armstrong, Scott A.; Zhu, Nan; Chen, Mo; Eng, Rowena; Chen, Chun-Wei // Journal of Clinical Investigation;3/1/2016, Vol. 126 Issue 3, p997 

    Self-renewal is a hallmark of both hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs); therefore, the identification of mechanisms that are required for LSC, but not HSC, function could provide therapeutic opportunities that are more effective and less toxic than current treatments....

  • Lnk constrains myeloproliferative diseases in mice. Bersenev, Alexey; Chao Wu; Balcerek, Joanna; Jiang Jing; Kundu, Mondira; Blobel, Gerd A.; Chikwava, Kudakwashe R.; Wei Tong; Wu, Chao; Jing, Jiang; Tong, Wei // Journal of Clinical Investigation;Jun2010, Vol. 120 Issue 6, p2058 

    Hematopoietic stem and progenitor cell (HSPC) expansion is regulated by intrinsic signaling pathways activated by cytokines. The intracellular kinase JAK2 plays an essential role in cytokine signaling, and activating mutations in JAK2 are found in a number of hematologic malignancies. We...

  • Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Ito, Takahiro; Kwon, Hyog Young; Zimdahl, Bryan; Congdon, Kendra L.; Blum, Jordan; Lento, William E.; Zhao, Chen; Lagoo, Anand; Gerrard, Gareth; Foroni, Letizia; Goldman, John; Goh, Harriet; Soo-Hyun Kim; Dong-Wook Kim; Chuah, Charles; Oehler, Vivian G.; Radich, Jerald P.; Jordan, Craig T.; Reya, Tannishtha // Nature;8/5/2010, Vol. 466 Issue 7307, p765 

    Chronic myelogenous leukaemia (CML) can progress from a slow growing chronic phase to an aggressive blast crisis phase, but the molecular basis of this transition remains poorly understood. Here we have used mouse models of CML to show that disease progression is regulated by the...

  • BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia. Leo, Elisa; Mancini, Manuela; Aluigi, Michela; Luatti, Simona; Castagnetti, Fausto; Testoni, Nicoletta; Soverini, Simona; Santucci, Maria Alessandra; Martinelli, Giovanni // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Beta Catenin signaling is critical for the self-renewal of leukemic stem cells in chronic myeloid leukemia. It is driven by multiple events, enhancing beta catenin stability and promoting its transcriptional co-activating function. We investigated the impact of BCR-ABL1 on Chibby1, a beta...

  • The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Mar, B G; Amakye, D; Aifantis, I; Buonamici, S // Leukemia (08876924);Nov2011, Vol. 25 Issue 11, p1665 

    Hedgehog (Hh) is a developmental signaling pathway in which Hh ligands bind Patched (Ptch), which relieves its inhibition of Smoothened (Smo), allowing the Gli family of transcription factors to translocate to the nucleus and activate Hh target genes. The role of Hh signaling in hematopoiesis is...

  • MEK kinase 1 is essential for Bcr–Abl-induced STAT3 and self-renewal activity in embryonic stem cells. Nakamura, Yukinori; Yujiri, Toshiaki; Nawata, Ryouhei; Tagami, Kozo; Tanizawa, Yukio // Oncogene;11/17/2005, Vol. 24 Issue 51, p7592 

    BCR–ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, arises in a primitive hematopoietic stem cell that has the capacity for both differentiation and self-renewal. Its product, Bcr–Abl protein, has been shown to activate signal transducers and activators of...

  • Inhibition of Ras-mediated signaling pathways in CML stem cells. Bertacchini, Jessika; Ketabchi, Neda; Mediani, Laura; Capitani, Silvano; Marmiroli, Sandra; Saki, Najmaldin // Cellular Oncology (2211-3428);Dec2015, Vol. 38 Issue 6, p407 

    Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the presence of the BCR-ABL1 oncoprotein in cells with a hematopoietic stem cell (HSC) origin. BCR-ABL1 tyrosine kinase activity leads to constitutive activation of Ras, which in turn acts as a...

  • Atypical chronic myeloid leukemia achieving good response with azacitidine. Marumo, Atsushi; Mizuki, Taro; Tanosaki, Sakae // Indian Journal of Cancer;Oct-Nov2019, Vol. 56 Issue 4, p354 

    The prognosis of atypical chronic myeloid leukemia (aCML) patients is poor, but some patients with a suitable donor can be treated with allogeneic hematopoietic stem cell transplantation (HSCT). However, many of these patients cannot be treated with HSCT due to their age. The effectiveness of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics